Ponatinib in the treatment of patients with chronic myeloid leukemia and increased cardiovascular risk: A review of management strategies
The introduction of tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia vastly improving the prognosis and clinical outcome of most patients. It was estimated that approximately 40–50 % of patients treated with imatinib will require treatment with a second-generat...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2025-01-01
|
| Серии: | Hematology, Transfusion and Cell Therapy |
| Предметы: | |
| Online-ссылка: | http://www.sciencedirect.com/science/article/pii/S2531137924002980 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|